title: Effect of parathyroid function on serum bone Gla protein.
abstract: The serum bone Gla protein (BGP) level was measured in patients with idiopathic hypoparathyroidism, and primary hyperparathyroidism, and normal volunteers. The mean serum BGP level was 4.5 +/- 0.20 micrograms/l in 40 normal volunteers. It was significantly lower in 12 patients with idiopathic hypoparathyroidism (1.6 +/- 0.21 micrograms/l, p less than 0.001) and significantly higher in 33 patients with primary hyperparathyroidism (13.0 +/- 1.3 micrograms/l, p less than 0.001). When a single intravenous injection of 30 micrograms of human PTH 1-34 was administered to the patients with idiopathic hypoparathyroidism, there was no significant change in serum BGP within the next 24 hours. Following a therapeutic oral dose of alfacalcidol, serum BGP was appreciably increased (p less than 0.001) from the preadministration value of 1.6 +/- 0.21 micrograms/l to 3.9 +/- 0.34 micrograms/l. In patients with primary hyperparathyroidism, the surgical excision of parathyroid adenoma led to a sharp decrease in serum PTH but a gradual decrease in serum BGP. The latter approximately paralleled the decline in serum alkaline phosphatase. Thus, serum BGP is a marker that reflects bone turnover status in parathyroid disease. It appears that the active form of vitamin D directly increases the secretion of BGP in existing osteoblasts and PTH mainly affects serum BGP to stimulate the bone remodeling cycles with its long term effect.
authors.affiliation: First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yoneda
authors.forename: K
authors.initials: K
authors.lastname: Takatsuki
authors.forename: K
authors.initials: K
authors.lastname: Yamauchi
authors.forename: Y
authors.initials: Y
authors.lastname: Oiso
authors.forename: M
authors.initials: M
authors.lastname: Kurokawa
authors.forename: A
authors.initials: A
authors.lastname: Kawakubo
authors.forename: Y
authors.initials: Y
authors.lastname: Torimoto
authors.forename: H
authors.initials: H
authors.lastname: Funahashi
authors.forename: A
authors.initials: A
authors.lastname: Tomita
mesh_terms: D000236:Adenoma / Q000601:surgery; D002118:Calcium / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006887:Hydroxycholecalciferols / Q000494:pharmacology / Q000627:therapeutic use; D006961:Hyperparathyroidism / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D007011:Hypoparathyroidism / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D015675:Osteocalcin; D010280:Parathyroid Glands / Q000502:physiology*; D010281:Parathyroid Hormone / Q000494:pharmacology / Q000627:therapeutic use; D010282:Parathyroid Neoplasms / Q000601:surgery; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D019379:Teriparatide; D013997:Time Factors
chemical_list: D002135:Calcium-Binding Proteins; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D015675:Osteocalcin; D019379:Teriparatide; D002118:Calcium; C008088:alfacalcidol